FDA authorizes marketing of diagnostic test that uses novel technology to detect MRSA bacteria

  06 December 2019

Today, the U.S. Food and Drug Administration authorized marketing of a new diagnostic test based on bacterial viability and novel technology to detect Methicillin-resistant Staphylococcus aureus (MRSA) bacterial colonization, a widespread cause of hospital-acquired infections. The cobas vivoDx MRSA diagnostic test may allow health care professionals to evaluate patients for colonization with MRSA bacteria more quickly than traditional culture-based techniques when such testing is needed.

Further reading: FDA
Author(s): FDA
Healthy Patients   Smart Innovations  

Registration now open:

International Masterclass AMR 29 SEP delivered digitally: 2 = 1!


  • Science, Health-Economic & Societal impact
  • Global causes and global solutions
  • Bottom-up, interactive approach
  • International Experts involved

Offered online!

Register today >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!